SEC Form 4 · accession 0001225208-18-000424
PFIZER INC · PFE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ian C Read
Officer — Chairman & CEO · Director
Period of report
Dec 29, 2017
Accepted (ET)
Jan 3, 2018 · 5:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000078003
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Appreciation RightsF1 | $36.22 | Dec 29, 2017 | A | 1,372,213 | A | Dec 29, 2022 | Dec 29, 2022 | Common Stock | 1,372,213 | 1,372,213 | D |
Explanation of responses
- F1The stock appreciation rights will settle on the fifth anniversary of the grant date (December 29, 2022) subject to both of the following requirements being met: (a) the reporting person remains continuously employed by Pfizer through March 31, 2019 (or such earlier time as determined by the Board of Directors) and he is either employed by Pfizer or is subject to. and complies with a non-compete and non-solicitation agreement until March 31, 2021 and (b) Pfizer's total shareholder return is at least 25% or higher on average for 30 consecutive trading days anytime within the five-year performance period (which ends on December 29, 2022).